

Market Surveillance Studies organised in the GEON

- MSS001 Amoxicillin solid preparations (1996)
- MSS002 Beclometasone pressurised metered dose preparations for inhalation (1996)
- MSS003 Salbutamol pressurised metered dose preparations for inhalation
- MSS004 Ranitidine oral preparations solid forms (1997)
- MSS005 Lithium modified release preparations (1997)
- MSS006 Diclofenac gastro-resistant tablets (1998)
- MSS007 Nifedipine oral preparations immediate release products (1999)
- MSS008 Tamoxifen citrate tablets (1999)
- MSS009 Salbutamol/salbutamol sulphate metered dose preparations for inhalation (1999)
- MSS010 Dihydrostreptomycin sulphate in veterinary suspensions for injection (2000)
- MSS012 Nifedipine retard products (2000)
- MSS013 Trimethoprim: impurities in raw materials and tablets (2000)
- MSS014 Doxycyclines in oral preparations for human and veterinary use (2000)
- MSS015 Erythromycin base and salts: solid preparations and bulk drug substances (2001)
- MSS016 Valerian root (2001)
- MSS017 Matricaria flower (2003)
- MSS018 Linseed: determination of cadmium content (2002)
- MSS019 Liquorice root (2002)
- MSS020 Aciclovir tablets (2003)
- MSS021 Amoxicillin granules and powders for oral suspensions (2003)
- MSS022 Ibuprofen and dexibuprofen tablets and capsules (2003)
- MSS023 Omeprazole capsules and tablets (2004)
- MSS025 Tablets for which subdivision is authorised (2004)
- MSS026 Erythromycin liquid preparations and erythromycin ester preparations (2006)

MSS027 Equisetum stem (2005)

MSS029 Trimethoprim 2: impurities in raw materials and tablets (2005)

MSS030 Uniformity of dosage units, *Ph. Eur. 2.9.40* (2004)

MSS031 Cadmium content in herbal drugs (2005)

MSS032 Diclofenac retard preparations (2006)

MSS033 Procaine-containing aqueous solutions for injection (2007)

MSS034 Essential oils: lavender, coriander and peppermint oil (2007)

MSS035 Lisinopril tablets (2008)

MSS036 Amoxicillin, clavulanic acid and prednisolone intramammary suspensions (2008)

MSS037 Levothyroxine tablets (2009)

MSS038 Analgesic (opioid) oral retard products (2009)

MSS039 Omeprazole gastro-resistant tablets and capsules (2008)

MSS040 Simvastatin tablets (2010)

MSS041 Acetylsalicylic acid oral products (2011)

MSS042 Alkyl mesitates in APIs and medicines presented as mesilate salts (2011)

MSS043 Clopidogrel APIs and tablets (2011)

MSS044 Heparin and low molecular mass heparin APIs and medicinal products (2012)

MSS045 Eye drops and nasal preparations classified as medical devices (2013)

MSS046 Telmisartan APIs and tablets (2014)

MSS047 Pramipexole APIs and tablets (2015)

MSS048 Subdivision of tablets (2015)

MSS049 Irbesartan APIs and tablets (2015)

MSS050 Hyaluronic Acid based dermal fillers (2017)

MSS051 Foreign Matter in herbal drugs (2016)

MSS052 Repaglinide tablets (2017)

MSS053 Leflunomide tablets (2016)

MSS054 Liothyronine API and tablets (2018)

MSS055 Zoledronic Acid preparations for parenteral application (2017)

MSS056 Meloxicam APIs and solutions for injection (2017)

MSS057 Pioglitazone tablets (2018)

MSS058 Sildenafil APIs and finished products (2020)

MSS059 Tadalafil APIs and tablets (2021)

MSS060 Olanzapine APIs and film-coated tablets (2022)

MSS061 Breaking of glass ampoules (2021)

MSS062 Pregabalin hard capsules (2023)

MSS063 Rosuvastatin APIs and tablets (2023)

MSS064 Medical face masks (2024)

MSS065 Disintegration of Alendronic acid tablets (2024)

MSS066 Lenalidomide APIs and capsules (2025), *in progress*

MSS067 Lacosamide finished products, *to be launched*

MSS068 Fingolimod APIs and hard capsules, *to be launched*